About our used conditions ratings:

·Like New: An apparently unread copy in excellent condition. The dust cover is intact, and the pages are clean and not marred by notes or folds of any kind.

·Very Good: A copy that has been read, but remains in excellent condition. May have writing on the inside cover but pages are unmarred.

·Good: A copy that has been read, but remains in clean condition. All pages and covers are intact. The spine may show signs of wear. Pages can include limited notes and highlighting, and the copy can include "From the library of" labels or previous owner inscriptions.

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field

This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.

Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:

·Fiscal consequences of curing hepatitis C

·mRNA vaccines and the race for a cure

·Why the government does not deserve a piece of Biopharma's profits

·Paying for drugs whose ultimate value is unknown

·The impact of reduced revenues on R&D

This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry. 0.35 pounds